Sana Louise Johnson-Quijada MD Viking Clinical Research Center Education La Sierra University, Riverside, CA BS Biology 1994 Loma Linda University, Loma Linda, CA MD Degree 1998 Licenseure/Certifications Massachusetts Board of Registration in Medicine 2001 California Medical Board 1998 HAM-A, HAM-D, MADRS, Jung Mania Scale, LSAS, BPRS, PANSS, CGI, SANS, QOL, SIMPSON-ANGUS, AIMS, SCID-I and SCID-II Internships and Residences Loma Linda University 2001 Department of Psychiatry Harvard South Shore 2002 Chief Resident in Psychiatry Medical Practice / Employment Investigator 2004-Present Temecula, CA 92591 Temecula Valley Psychiatric Medical Group July 2004-Present Private Practice Temecula, CA 92590 Sana Johnson-Quijada, M.D., Inc. Sept 2002-July 2004 Private Practice Redlands, CA 92373 Service Director, Staff Psychiatrist Sept 2002-Present Canyon Ridge Hospital Chino, CA 91710
Staff Psychiatrist Sept 2002 - Jan 2003 California Rehabilitation Center Norco, CA 92860 Faulkner Hospital Boston, MA 02130 Mt. Auburn Hospital Cambridge, MA 02138 Newton-Wellesley Hospital Newton, MA 02462 Cambridge Psychiatric Services Cambridge, MA 02138 House- Staff Psychiatrist Jul 2001-Aug 2002 Harvard South Shore Brockton, MA 02401 Staff Psychiatrist Mar 2001-Jun 2001 Inland AIDS Clinic San Bernardino, CA 92405 Staff Psychiatrist Mar 2001-Jun 2001 Kaiser Permanente Fontana, CA 92335 Staff Psychiatrist Dec 2000-Mar 2001 Temecula Psychiatric Services Temecula, CA 92591 House Staff Psychiatrist Sept 1998-Jun 2001 Loma Linda University Loma Linda, CA 92354
Hospital Appointments Canyon Ridge Hospital 2002-Present Chino, CA California Rehabilitation Center 2002-2003 Norco, CA Faulkner Hospital 2002 Boston, MA Mt. Auburn Hospital 2002 Cambridge, MA Newton-Wellesley Hospital 2002 Newton, MA Cambridge Psychiatric Services 2002 Cambridge, MA Harvard South Shore 2001-2002 Brockton, MA Inland AIDS Clinic 2001 San Bernardino, CA Kaiser Permanente 2001 Fontana, CA Temecula Psychiatric Services 2000 Temecula, CA Professional Societies American Psychiatric Association 1997 Invited Presentations Sleep Disorders 2003 Rotary Club, Corona
Lake Arrowhead Teaching Seminar for the local community (Depression) 2001 20-25 patients; 1 session/year; 3 hours/year Harvard Medical School Instructor, Introduction to Clinical Medicine for second year Harvard Medical School students 2002 7 students/section; 2 sections/year; 6 hours/year Faculty and Medical House Staff Teaching Conference 2002 (Somatoform Disorders) 15-20 residents; 3 hours/month; 24 hours/year Faculty, Physical Medicine and Rehabilitation Teaching Conference 2002 (Character Disorders, Somatoform Disorders) 4-5 faculty; 2 hours/week; 4 hours/year Individual Supervision for PGY III residents 2002 Harvard Southshore Department of Psychiatry West Roxbury Division 1 resident every 2 months; 8 hours/day; 2088 hours/year Depression in the Terminally Ill 2004 Annual Postgraduate Convention Management of the Frequent Flyer: Somatoform Disorders 2002 Internal Medicine Conference Management of the Frequent Flyer: Somatoform Disorders 2002 Spinal Cord Injury Medicine Conference, Management of Patients with Character Disorders 2002 Spinal Cord Injury Medicine Conference,
Smoking Cessation Lecture Series 2001 Jerry L. Pettis Veterans Hospital Visual Hallucinations 2001 Psychiatry Grand Rounds Befriending the Depressed 1998 Ambulatory Care Update Invited Presentations Book Chapter Mufson M, Quijada SLJ. Panic: Origins, Insight, and Treatment. In: Warner B (ed.). California: Atlantic Books, 2002. Clinical Research GlaxoSmithKline: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended- Release Bupropion Hydrochloride (xxxmg-xxxmg once daily) in Elderly Subjects with Major Depressive Disorder. 2004-2005. GlaxoSmithKline: A Twelve-Week, Multi-Center, Randomized, Double-Blind, Double- Dummy, Parallel-Group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-Release (WELLBUTRINÔSL, xxxxxxmg/day) and Extended-Release Venlafaxine (EFFEXOR XR, xx-xxxmg/day) in Subjects with Major Depressive Disorder. 2004-2005. Pfizer: A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects with Bipolar Disorder to Evaluate the Continued Safety and Maintenance of Effect of XXX Plus a Mood Stabilizer (Vs. Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment with Both Agents. 2006-2007. Sanofi Aventis: An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with XXX as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of XX in Outpatients with MDD. 2006-2007. Novartis: An 8-Week, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Multi- Center Study of the Efficacy, Safety and Tolerability of XXX xx and xx mg in the Treatment of Major Depressive Disorder (MDD). 2006-2007.
GlaxoSmithKline: A 12 Week Flexible Dose Study of XXX, Placebo and Active Control in the Treatment of Social Anxiety Disorder (SocAD). 2006-2007. Sanofi-Aventis: A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm, Placebo and XXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXX in Adult Outpatients with Major Depressive Disorder. 2007. Novartis: An 8 week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled Parallel Group, Multi-Center Study of the Safety, Efficacy, and Tolerability of XXX 25mg and 50mg in the Treatment of Major Depressive Disorder Followed by a 52 Week, Open-Label Extension 2007-2008 Pfizer: A Sixteen-Week, Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Switching From Quetiapine to Ziprasidone in Subjects Diagnosed with Schizophrenia or Schizoaffective Disorder 2008 Pfizer: A Phase 3, Randomized, Double-Blind, Parallel Group, Controlled Fixed Dose Study of XXX and XXXX in Evaluating the Efficacy and Safety of XXX for the Treatment of Generalized Anxiety Disorder 2008-2009 Pfizer: A Phase 3, 52-Week, Open-Label Safety Study of XXX in Subjects With Generalized Anxiety Disorder 2008-2009 Wyeth: An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients with Depression 2009